Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study

A. Chari, P. Rodriguez-Otero, H. McCarthy, K. Suzuki, V. Hungria, A. Sureda Balari, A. Perrot, C. Hulin, H. Magen, S. Iida, V. Maisnar, L. Karlin, L. Pour, DA. Parasrampuria, T. Masterson, M. Kosh, S. Yang, M. Delioukina, M. Qi, R. Carson, C. Touzeau

. 2021 ; 192 (5) : 869-878. [pub] 20200730

Jazyk angličtina Země Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025997

Grantová podpora
Janssen Research and Development, LLC
Janssen Global Services, LLC

Daratumumab is a CD38-targeting monoclonal antibody approved for intravenous (IV) infusion for multiple myeloma (MM). We describe the Phase II PLEIADES study of a subcutaneous formulation of daratumumab (DARA SC) in combination with standard-of-care regimens: DARA SC plus bortezomib/lenalidomide/dexamethasone (D-VRd) for transplant-eligible newly diagnosed MM (NDMM); DARA SC plus bortezomib/melphalan/prednisone (D-VMP) for transplant-ineligible NDMM; and DARA SC plus lenalidomide/dexamethasone (D-Rd) for relapsed/refractory MM. In total, 199 patients were treated (D-VRd, n = 67; D-VMP, n = 67; D-Rd, n = 65). The primary endpoints were met for all cohorts: the ≥very good partial response (VGPR) rate after four 21-day induction cycles for D-VRd was 71·6% [90% confidence interval (CI) 61·2-80·6%], and the overall response rates (ORRs) for D-VMP and D-Rd were 88·1% (90% CI 79·5-93·9%) and 90·8% (90% CI 82·6-95·9%). With longer median follow-up for D-VMP and D-Rd (14·3 and 14·7 months respectively), responses deepened (ORR: 89·6%, 93·8%; ≥VGPR: 77·6%, 78·5%), and minimal residual disease-negativity (10-5 ) rates were 16·4% and 15·4%. Infusion-related reactions across all cohorts were infrequent (≤9·0%) and mild. The median DARA SC administration time was 5 min. DARA SC with standard-of-care regimens demonstrated comparable clinical activity to DARA IV-containing regimens, with low infusion-related reaction rates and reduced administration time.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025997
003      
CZ-PrNML
005      
20211026133314.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.16980 $2 doi
035    __
$a (PubMed)33216361
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Chari, Ajai $u Icahn School of Medicine at Mount Sinai, New York, NY, USA
245    10
$a Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study / $c A. Chari, P. Rodriguez-Otero, H. McCarthy, K. Suzuki, V. Hungria, A. Sureda Balari, A. Perrot, C. Hulin, H. Magen, S. Iida, V. Maisnar, L. Karlin, L. Pour, DA. Parasrampuria, T. Masterson, M. Kosh, S. Yang, M. Delioukina, M. Qi, R. Carson, C. Touzeau
520    9_
$a Daratumumab is a CD38-targeting monoclonal antibody approved for intravenous (IV) infusion for multiple myeloma (MM). We describe the Phase II PLEIADES study of a subcutaneous formulation of daratumumab (DARA SC) in combination with standard-of-care regimens: DARA SC plus bortezomib/lenalidomide/dexamethasone (D-VRd) for transplant-eligible newly diagnosed MM (NDMM); DARA SC plus bortezomib/melphalan/prednisone (D-VMP) for transplant-ineligible NDMM; and DARA SC plus lenalidomide/dexamethasone (D-Rd) for relapsed/refractory MM. In total, 199 patients were treated (D-VRd, n = 67; D-VMP, n = 67; D-Rd, n = 65). The primary endpoints were met for all cohorts: the ≥very good partial response (VGPR) rate after four 21-day induction cycles for D-VRd was 71·6% [90% confidence interval (CI) 61·2-80·6%], and the overall response rates (ORRs) for D-VMP and D-Rd were 88·1% (90% CI 79·5-93·9%) and 90·8% (90% CI 82·6-95·9%). With longer median follow-up for D-VMP and D-Rd (14·3 and 14·7 months respectively), responses deepened (ORR: 89·6%, 93·8%; ≥VGPR: 77·6%, 78·5%), and minimal residual disease-negativity (10-5 ) rates were 16·4% and 15·4%. Infusion-related reactions across all cohorts were infrequent (≤9·0%) and mild. The median DARA SC administration time was 5 min. DARA SC with standard-of-care regimens demonstrated comparable clinical activity to DARA IV-containing regimens, with low infusion-related reaction rates and reduced administration time.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D000911
650    _2
$a protinádorové látky imunologicky aktivní $x aplikace a dávkování $x škodlivé účinky $7 D000074322
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a bortezomib $x aplikace a dávkování $7 D000069286
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a dexamethason $x aplikace a dávkování $7 D003907
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a krevní nemoci $x chemicky indukované $7 D006402
650    _2
$a lidé $7 D006801
650    12
$a imunoterapie $7 D007167
650    _2
$a lenalidomid $x aplikace a dávkování $7 D000077269
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melfalan $x aplikace a dávkování $7 D008558
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    _2
$a prednison $x aplikace a dávkování $7 D011241
650    _2
$a standardní péče $7 D059039
650    _2
$a výsledek terapie $7 D016896
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rodriguez-Otero, Paula $u Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain
700    1_
$a McCarthy, Helen $u Royal Bournemouth Hospital, Bournemouth, UK
700    1_
$a Suzuki, Kenshi $u Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
700    1_
$a Hungria, Vania $u Clinica Medica São Germano, São Paulo, Brazil
700    1_
$a Sureda Balari, Anna $u Hematology Department, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain
700    1_
$a Perrot, Aurore $u CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France
700    1_
$a Hulin, Cyrille $u Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France
700    1_
$a Magen, Hila $u Department of Hematology Chaim Sheba Medical Center, Ramat-Gan, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Iida, Shinsuke $u Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
700    1_
$a Maisnar, Vladimir $u 4th Department of Medicine - Haematology, Charles University Hospital, Hradec Králové, Czech Republic
700    1_
$a Karlin, Lionel $u Department of Hematology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France
700    1_
$a Pour, Ludek $u University Hospital Brno, Brno, Czech Republic
700    1_
$a Parasrampuria, Dolly A $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a Masterson, Tara $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a Kosh, Michele $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a Yang, Shiyi $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a Delioukina, Maria $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a Qi, Ming $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a Carson, Robin $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a Touzeau, Cyrille $u Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 192, č. 5 (2021), s. 869-878
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33216361 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133320 $b ABA008
999    __
$a ok $b bmc $g 1714875 $s 1146504
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 192 $c 5 $d 869-878 $e 20200730 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
GRA    __
$p Janssen Research and Development, LLC
GRA    __
$p Janssen Global Services, LLC
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace